Place of anti-IL6R in the therapeutic strategy in NMOSD-AQP4+, MOGAD, and NMOSD double-seronegative patients. Comet C, Jouvenot G, Bourre B, Ciron J, et al. Mult Scler 2026;32:214-223.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Comet C, Jouvenot G, Bourre B, Ciron J, et al. Place of anti-IL6R in the therapeutic strategy in NMOSD-AQP4+, MOGAD, and NMOSD double-seronegative patients. Mult Scler 2026;32:214-223.
PMID: 41404646